Epidemiology and outcomes of novel coronavirus 2019 in patients with immune-mediated inflammatory diseases.
Curr Opin Rheumatol
; 32(5): 434-440, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: covidwho-649601
ABSTRACT
PURPOSE OF REVIEW The novel coronavirus 2019 (COVID-19) pandemic is of special concern for patients with immune-mediated inflammatory disease (IMID) and those who care for them because of the potential for worse outcomes. This article analyzes peer-reviewed research on the epidemiology and outcomes of COVID-19 in those with IMID. RECENT FINDINGS:
Published literature on approximately 1400 patients was included from rheumatology, gastroenterology, and dermatology. Data suggest that those who are older and have comorbidities have poorer outcomes. This is consistent with the reports from the general population of patients with COVID-19. Adjusted analyses from the largest published studies demonstrate independent effects of systemic glucocorticoids, as well as age and comorbidities with poorer COVID-19 outcomes (SECURE-IBD registry, nâ=â525; COVID-19 Global Rheumatology Alliance registry, nâ=â600); biologic or targeted synthetic disease-modifying antirheumatic drug therapy has not been associated with more severe outcomes. These early results will require validation in population-based studies as more data becomes available.SUMMARY:
Current data suggest that similar to the general population, age, and comorbidities are risk factors for poorer COVID-19 outcomes in patients with IMID. Additional research is needed to quantify outcomes and risk across rheumatic disease types, comorbidities, and immunosuppressive drugs.
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Neumonía Viral
/
Enfermedades Reumáticas
/
Infecciones por Coronavirus
/
Betacoronavirus
Tipo de estudio:
Estudio observacional
/
Estudio pronóstico
Tópicos:
Covid persistente
Límite:
Humanos
Idioma:
Inglés
Revista:
Curr Opin Rheumatol
Asunto de la revista:
Reumatología
Año:
2020
Tipo del documento:
Artículo
País de afiliación:
Bor.0000000000000725
Similares
MEDLINE
...
LILACS
LIS